BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kayhanian H, Smyth EC, Braconi C. Emerging molecular targets and therapy for cholangiocarcinoma. World J Gastrointest Oncol 2017; 9(7): 268-280 [PMID: 28808500 DOI: 10.4251/wjgo.v9.i7.268]
URL: https://www.wjgnet.com/1948-5204/full/v9/i7/268.htm
Number Citing Articles
1
Marin Strijker, Ali Belkouz, Lydia G. van der Geest, Thomas M. van Gulik, Jeanin E. van Hooft, Vincent E. de Meijer, Nadia Haj Mohammad, Philip R. de Reuver, Joanne Verheij, Judith de Vos-Geelen, Johanna W. Wilmink, Bas Groot Koerkamp, Heinz-Josef Klümpen, Marc G. Besselink. Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide studyActa Oncologica 2019; 58(7): 1048 doi: 10.1080/0284186X.2019.1590634
2
Samantha Sarcognato, Iris E. M. de Jong, Luca Fabris, Massimiliano Cadamuro, Maria Guido. Necroptosis in CholangiocarcinomaCells 2020; 9(4): 982 doi: 10.3390/cells9040982
3
Tommaso M Manzia, Alessandro Parente, Ilaria Lenci, Bruno Sensi, Martina Milana, Carlo Gazia, Alessandro Signorello, Roberta Angelico, Giuseppe Grassi, Giuseppe Tisone, Leonardo Baiocchi. Moving forward in the treatment of cholangiocarcinomaWorld Journal of Gastrointestinal Oncology 2021; 13(12): 1939-1955 doi: 10.4251/wjgo.v13.i12.1939
4
Wei-xun Chen, Gan-xun Li, Zheng-nan Hu, Peng Zhu, Bi-xiang Zhang, Ze-yang Ding. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasisMedicine 2019; 98(45): e17832 doi: 10.1097/MD.0000000000017832
5
Wei Zhong, Lianzhi Dai, Jing Liu, Song Zhou. Cholangiocarcinoma‑associated genes identified by integrative analysis of gene expression dataMolecular Medicine Reports 2018;  doi: 10.3892/mmr.2018.8594
6
Oded Jacobi, Jeffrey S. Ross, Tal Goshen-Lago, Riad Haddad, Assaf Moore, Aaron Sulkes, Baruch Brenner, Irit Ben-Aharon. ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable PathwayOncology Research and Treatment 2021; 44(1-2): 20 doi: 10.1159/000511919
7
Meena Sadaps, Davendra P.S. Sohal. Remarkable Case of Dual BRAF and MEK Inhibition in CholangiocarcinomaJCO Precision Oncology 2019; (3): 1 doi: 10.1200/PO.19.00056
8
Chen Liu, Min Wang, Haitao Lv, Bing Liu, Xueqiang Ya, Weihong Zhao, Wenbin Wang. CEACAM6 promotes cholangiocarcinoma migration and invasion by inducing epithelial‑mesenchymal transition through inhibition of the SRC/PI3K/AKT signaling pathwayOncology Letters 2021; 23(1) doi: 10.3892/ol.2021.13157
9
Samantha Sarcognato, Enrico Gringeri, Matteo Fassan, Michela Di Giunta, Valeria Maffeis, Vincenza Guzzardo, Umberto Cillo, Maria Guido. Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinomaVirchows Archiv 2019; 474(1): 29 doi: 10.1007/s00428-018-2478-y
10
Thorsten O. Goetze, Wolf O. Bechstein, Ulli Simone Bankstahl, Tobias Keck, Alfred Königsrainer, Sven A. Lang, Claudia Pauligk, Pompiliu Piso, Arndt Vogel, Salah-Eddin Al-Batran. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)– the AIO/ CALGP/ ACO- GAIN-trial –BMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-6610-4
11
Nicolás Goldaracena, Andre Gorgen, Gonzalo Sapisochin. Current status of liver transplantation for cholangiocarcinomaLiver Transplantation 2018; 24(2): 294 doi: 10.1002/lt.24955
12
Keun Soo Ahn, Koo Jeong Kang. Molecular heterogeneity in intrahepatic cholangiocarcinomaWorld Journal of Hepatology 2020; 12(12): 1148-1157 doi: 10.4254/wjh.v12.i12.1148
13
Alessandra Gentilini, Alessandra Caligiuri, Chiara Raggi, Krista Rombouts, Massimo Pinzani, Giulia Lori, Margherita Correnti, Pietro Invernizzi, Elisabetta Rovida, Nadia Navari, Sabina Di Matteo, Domenico Alvaro, Jesus M. Banales, Pedro Rodrigues, Carlotta Raschioni, Matteo Donadon, Luca Di Tommaso, Fabio Marra. CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cellsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2019; 1865(9): 2246 doi: 10.1016/j.bbadis.2019.04.020
14
Kira Astakhova, Roslyn Ray, Maria Taskova, Jesper Uhd, Annika Carstens, Kevin Morris. “Clicking” Gene Therapeutics: A Successful Union of Chemistry and Biomedicine for New SolutionsMolecular Pharmaceutics 2018; 15(8): 2892 doi: 10.1021/acs.molpharmaceut.7b00765
15
Marianeve Carotenuto, Alessandra Sacco, Laura Forgione, Nicola Normanno. Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapyExploration of Targeted Anti-tumor Therapy 2022; : 200 doi: 10.37349/etat.2022.00079
16
Pasquale Lombardi, Donatella Marino, Elisabetta Fenocchio, Giovanna Chilà, Massimo Aglietta, Francesco Leone. Emerging molecular target antagonists for the treatment of biliary tract cancerExpert Opinion on Emerging Drugs 2018; 23(1): 63 doi: 10.1080/14728214.2018.1444749
17
Lei Zhang, Martin H. Bluth, Amarpreet Bhalla. Molecular Diagnostics in the Neoplasms of the Pancreas, Liver, Gallbladder, and Extrahepatic Biliary TractClinics in Laboratory Medicine 2018; 38(2): 367 doi: 10.1016/j.cll.2018.03.003
18
Hongsik Kim, Ryul Kim, Hye Ryeon Kim, Hyunji Jo, Hana Kim, Sang Yun Ha, Joon Oh Park, Young Suk Park, Seung Tae Kim. HER2 Aberrations as a Novel Marker in Advanced Biliary Tract CancerFrontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.834104